Io Therapeutics is discovering and developing a series of retinoid and rexinoid small molecules for the treatment of cancers, neurodegenerative diseases, and autoimmune diseases. The company’s lead program is development of IRX4204, a small molecule RXR agonist. The company’s focus with IRX4204 is treatment of HER2-positive breast cancer, multiple sclerosis, and Parkinson’s disease.
The company’s second clinical stage program is development of IRX5183, a small molecule RARα agonist for the treatment of acute myeloid leukemias, and multiple myeloma.
The company has drug-discovery programs for use of retinoid and rexinoid small molecule analogs to improve anti-cancer responses to checkpoint inhibitors, and chimeric antigen receptor modified immune cells.